Immupharma PlcLSE: IMM

Audited Report & Accounts published on website

Apr 30, 2020 at 8:57 AM UTC

Watch Immupharma explain itIMMUPHARMA PLC (IMM) — Corporate Update · Replay · Mar 20

RNS Number : 4797L

Immupharma PLC

30 April 2020

RNS: RELEASE 30 April 2020

ImmuPharma PLC

("ImmuPharma" or the "Company")

Audited Report & Accounts published on website

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company confirms that the Audited Annual Report and Accounts ("Report") for the year ended 31 December 2019, has today been published on the Company's website. Copies of this Report, including the Notice of Annual General Meeting, will be posted to shareholders in the near future.

Confirmation of this date will be announced to the market on the day of posting. To view the Report please go to: www.immupharma.co.uk.

For further information please contact:

ImmuPharma PLC ( www.immupharma.com ) Tim McCarthy, Chairman	+ 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD) Neil Baldwin Stanford Capital Partners (Joint Broker) Patrick Claridge, John Howes SI Capital (Joint Broker) Nick Emerson	+44 (0) 203 368 8974 +44 (0) 203 815 8880 +44 (0) 1483 413500
4Reliance (Euronext Growth Listing Sponsor) Jean-Charles Snoy Degroof Petercam (Liquidity Provider) Erik De Clippel Backstage Communication Olivier Duquaine Gunther De Backer	+32 (0) 2 747 02 60 +32 (0) 2 287 95 34 +32 (0) 477 504 784 +32 (0) 475 903 909

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

ACSIMMPTMTAJMJM